
JP Morgan initiated coverage of Cidara Therapeutics Inc. (NASDAQ:CDTX) on Friday, citing its lead asset, CD388, for influenza, underscoring the game-changing potential of the product and multi-billion dollar potential in the U.S. alone.
Analyst Anupam Rama says across doses, prevention efficacy was ahead of known vaccine benchmarks across various populations, with the highest dose (450mg) showing a prevention efficacy of around 76% with no major safety concerns.